119.00
-2.00
(-1.65%)
As of 8:01:28 AM GMT+1. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director | -- | -- | 1960 |
| Mr. Scott T. Smith | CFO, Executive VP & Member of Executive Board | -- | -- | 1974 |
| Ms. Lotte Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | -- | -- | 1961 |
| Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board | -- | -- | 1971 |
| Mr. Mads Bodenhoff | Senior VP of Finance & Principal Accounting Officer | -- | -- | -- |
| Mr. Timothy J. Lee | Senior Director of Investor Relations | -- | -- | -- |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | -- | -- | 1961 |
| Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development | -- | -- | 1979 |
| Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology | -- | -- | 1974 |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology | -- | -- | 1969 |
Ascendis Pharma A/S
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 879
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Corporate Governance
Ascendis Pharma A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
February 5, 2025 at 10:59 AM UTC - February 10, 2025 at 12:00 PM UTC
Ascendis Pharma A/S Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
83B.F 3SBio Inc.
0.7500
+1.35%
RV7.F Halozyme Therapeutics, Inc.
52.64
-0.64%
TRSBF 3SBio Inc.
0.8279
0.00%
2CL.BE BridgeBio Pharma Inc
34.63
-1.20%
1530.HK 3SBIO
6.210
+1.14%
ARGX argenx SE
648.94
-0.50%
IPA ImmunoPrecise Antibodies Ltd.
0.5765
-3.92%
VKTX Viking Therapeutics, Inc.
34.50
-1.26%
RXRX Recursion Pharmaceuticals, Inc.
7.33
-2.66%